Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 113

1.

Anatomic study of the arterial territories of the face depending on the external carotid artery branches.

Touzet-Roumazeille S, Nicol P, Fontaine C, Vacher C.

Morphologie. 2019 Sep 4. pii: S1286-0115(19)30049-9. doi: 10.1016/j.morpho.2019.08.002. [Epub ahead of print]

PMID:
31494018
2.

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial.

Ray KK, Colhoun HM, Szarek M, Baccara-Dinet M, Bhatt DL, Bittner VA, Budaj AJ, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Loizeau V, Lopes RD, Moryusef A, Murin J, Pordy R, Ristic AD, Roe MT, Tuñón J, White HD, Zeiher AM, Schwartz GG, Steg PG; ODYSSEY OUTCOMES Committees and Investigators.

Lancet Diabetes Endocrinol. 2019 Aug;7(8):618-628. doi: 10.1016/S2213-8587(19)30158-5. Epub 2019 Jul 1. Erratum in: Lancet Diabetes Endocrinol. 2019 Jul 8;:. Lancet Diabetes Endocrinol. 2019 Sep;7(9):e21.

PMID:
31272931
3.

Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial.

Pieber TR, Bode B, Mertens A, Cho YM, Christiansen E, Hertz CL, Wallenstein SOR, Buse JB; PIONEER 7 investigators.

Lancet Diabetes Endocrinol. 2019 Jul;7(7):528-539. doi: 10.1016/S2213-8587(19)30194-9. Epub 2019 Jun 9. Erratum in: Lancet Diabetes Endocrinol. 2019 Sep;7(9):e21.

PMID:
31189520
4.

Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial.

Mosenzon O, Blicher TM, Rosenlund S, Eriksson JW, Heller S, Hels OH, Pratley R, Sathyapalan T, Desouza C; PIONEER 5 Investigators.

Lancet Diabetes Endocrinol. 2019 Jul;7(7):515-527. doi: 10.1016/S2213-8587(19)30192-5. Epub 2019 Jun 9. Erratum in: Lancet Diabetes Endocrinol. 2019 Sep;7(9):e21.

PMID:
31189517
5.

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.

Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riesmeyer JS, Riddle MC, Rydén L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T; REWIND Investigators.

Lancet. 2019 Jul 13;394(10193):121-130. doi: 10.1016/S0140-6736(19)31149-3. Epub 2019 Jun 9.

PMID:
31189511
6.

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.

Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Botros FT, Riddle MC, Rydén L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T; REWIND Investigators.

Lancet. 2019 Jul 13;394(10193):131-138. doi: 10.1016/S0140-6736(19)31150-X. Epub 2019 Jun 9.

PMID:
31189509
7.

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.

Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW; CREDENCE Trial Investigators.

N Engl J Med. 2019 Jun 13;380(24):2295-2306. doi: 10.1056/NEJMoa1811744. Epub 2019 Apr 14.

PMID:
30990260
8.

Feedback learning opportunities from medical student logs of paediatric patients.

Wright HM, Maley MAL, Playford DE, Nicol P, Evans SF.

BMC Med Educ. 2019 Apr 11;19(1):107. doi: 10.1186/s12909-019-1533-y.

9.

The transverse facial artery and the mandibular condylar process: An anatomic and radiologic study.

Nicol P, Uhl JF, Bertolus C, Vacher C.

J Stomatol Oral Maxillofac Surg. 2019 Sep;120(4):341-346. doi: 10.1016/j.jormas.2019.04.002. Epub 2019 Apr 6.

PMID:
30965155
10.

The parapharyngeal adipose corpus: anatomic and radiologic study.

Nicol P, Constans JM, d'Ortho MP, Goudot P, Vacher C.

Surg Radiol Anat. 2019 Jul;41(7):809-813. doi: 10.1007/s00276-019-02230-x. Epub 2019 Apr 3.

PMID:
30944977
11.

Serum amyloid A levels are associated with polymorphic variants in the serum amyloid A 1 and 2 genes.

Griffiths K, Maxwell AP, McCarter RV, Nicol P, Hogg RE, Harbinson M, McKay GJ.

Ir J Med Sci. 2019 Mar 9. doi: 10.1007/s11845-019-01996-8. [Epub ahead of print]

PMID:
30852808
12.

In vivo validation of Dosemap software use in interventional cardiology with dosimetrics indicators and peak skin dose evaluation.

Didier R, Bourhis D, Oueslati C, Nasr B, Le Ven F, Noël A, Jobic Y, Damien P, Pene-Baverez D, Mansourati J, Nicol PP, Gilard M.

Catheter Cardiovasc Interv. 2019 Aug 1;94(2):216-222. doi: 10.1002/ccd.28097. Epub 2019 Feb 4.

PMID:
30719828
13.

SerpinA3N is a novel hypothalamic gene upregulated by a high-fat diet and leptin in mice.

Sergi D, Campbell FM, Grant C, Morris AC, Bachmair EM, Koch C, McLean FH, Muller A, Hoggard N, de Roos B, Porteiro B, Boekschoten MV, McGillicuddy FC, Kahn D, Nicol P, Benzler J, Mayer CD, Drew JE, Roche HM, Muller M, Nogueiras R, Dieguez C, Tups A, Williams LM.

Genes Nutr. 2018 Nov 29;13:28. doi: 10.1186/s12263-018-0619-1. eCollection 2018.

14.

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.

Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM; ODYSSEY OUTCOMES Committees and Investigators.

N Engl J Med. 2018 Nov 29;379(22):2097-2107. doi: 10.1056/NEJMoa1801174. Epub 2018 Nov 7.

PMID:
30403574
15.

No effect of thymosin beta-4 on the expression of the transcription factor Islet-1 in the adult murine heart.

Weinberger F, Nicol P, Starbatty J, Stubbendorff M, Becher PM, Schrepfer S, Eschenhagen T.

Pharmacol Res Perspect. 2018 Jun;6(3):e00407. doi: 10.1002/prp2.407.

16.

Comparison of four methods to assess high-on platelet reactivity under P2Y12 receptor inhibitor.

Mingant F, Didier R, Gilard M, Martin F, Nicol PP, Ugo V, Lippert E, Galinat H.

Platelets. 2018 May;29(3):257-264. doi: 10.1080/09537104.2018.1453058. Epub 2018 Mar 26.

PMID:
29580115
17.

HIV-exposure, early life feeding practices and delivery mode impacts on faecal bacterial profiles in a South African birth cohort.

Claassen-Weitz S, Gardner-Lubbe S, Nicol P, Botha G, Mounaud S, Shankar J, Nierman WC, Mulder N, Budree S, Zar HJ, Nicol MP, Kaba M.

Sci Rep. 2018 Mar 22;8(1):5078. doi: 10.1038/s41598-018-22244-6.

18.

The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics.

Jardine MJ, Mahaffey KW, Neal B, Agarwal R, Bakris GL, Brenner BM, Bull S, Cannon CP, Charytan DM, de Zeeuw D, Edwards R, Greene T, Heerspink HJL, Levin A, Pollock C, Wheeler DC, Xie J, Zhang H, Zinman B, Desai M, Perkovic V; CREDENCE study investigators.

Am J Nephrol. 2017 Dec 13;46(6):462-472. doi: 10.1159/000484633. [Epub ahead of print]

19.

[Acyclovir-resistant perineal HSV infection revealing chronic lymphoid leukaemia].

Casassa EA, Nicol P, Viraben R, Gaudin C, Bulai Livideanu C, Mengelle C, Lamant L, Fortenfant F, Paul C, Konstantinou MP.

Ann Dermatol Venereol. 2018 Mar;145(3):182-186. doi: 10.1016/j.annder.2017.10.013. Epub 2017 Dec 6. French.

PMID:
29221652
20.

Paediatric case mix in a rural clinical school is relevant to future practice.

Wright HM, Maley MAL, Playford DE, Nicol P, Evans SF.

BMC Med Educ. 2017 Nov 29;17(1):237. doi: 10.1186/s12909-017-1082-1. Review.

Supplemental Content

Loading ...
Support Center